

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074802 A2

- (51) International Patent Classification⁷: **C07K 14/445**
- (21) International Application Number: PCT/US02/08307
- (22) International Filing Date: 18 March 2002 (18.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/277,002 19 March 2001 (19.03.2001) US
- (71) Applicant (*for all designated States except US*): **WALTER REED ARMY INSTITUTE OF RESEARCH** [US/US];
Dept. of the Army, Walter Reed Army Medical Center,
Washington, DC 20307-5100 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **LANAR, David, E.** [US/US]; 7401 Holly Avenue, Takoma Park, MD 20912 (US). **DUTTA, Sheetij** [US/US]; 2550 Ross Road #103, Silver Spring, MD 20910 (US). **WARE, Lisa, A.** [US/US]; 3408 Beret Lane, Silver Spring, MD 20906 (US).
- (74) Agent: **PRATT, Sana, A.**; Pratt & Associates, Inc., 10821 Hillbrooke Lane, Potomac, MD 20854 (US).
- (81) Designated States (*national*): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: RECOMBINANT *P. VIVAX* MEROZOITE PROTEIN-1 P42 VACCINE

(57) Abstract: In this application is the expression and purification of a recombinant *Plasmodium vivax* (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.



WO 02/074802 A2